Related Experiment Video
Updated: Jan 22, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer
Youjin Kim1,2, Sun-Ju Byeon3,4, Joonyoung Hur1
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract:
Background: Emerging evidence suggests that delta-like ligand 4 (DLL4) and other members of the Notch pathway may offer new targets for development of anti-angiogenesis drugs for the treatment of several tumor types. However, the role of DLL4 in gastric cancer (GC) remains unclear. In this study, we investigated the impact of DLL4 overexpression on recurrence and survival in gastric cancer (GC) patients. Methods: DLL4 expression levels were evaluated by immunohistochemistry in tissue samples from 336 GC patients. Samples were classified into high and low DLL4 expression according to a cut-off of 50% positively stained cells. The correlation between DLL4 expression and clinicopathological parameters, disease-free survival (DFS), and overall survival (OS) were statistically analyzed. Results: High DLL4 expression was observed in 67 (19.9%) of the 336 GC patients. After a median follow-up duration of 54.97 months [95% confidence interval (CI), 52.40-57.55 months), patients at stage II-IV with high DLL4 expression showed significantly poorer DFS compared with those at the same stage but with low DLL4 expression [not reached (NR) for both cohorts, hazard ratio (HR) 0.73 (95% CI, 0.38-1.40); p = 0.007]. Likewise, GC patients with high DLL4 expression had a significantly shorter OS following curative surgery compared to those with low DLL4 expression [NR for both groups, HR 0.56 (95% CI, 0.32-0.96; p = 0.002]. High DLL4 expression had a greater influence on DFS in stage IIIb/IV patients than in patients at early stages [34.87 vs. 10.1 months; HR, 0.44 (95% CI, 0.19-0.96); p = 0.004]. Moreover, stage IIIb/IV patients with high DLL4 expression had a significantly shorter OS after surgery than those with low DLL4 expression [58.87 vs. 16.93 months, HR 0.39 (95% CI, 0.16-0.99), p = 0.001). Conclusion: High DLL4 expression was observed in 19.9% of GC patients and was significantly associated with poor survival following curative surgery. Given its prevalence in the GC cohort with a poor prognosis, DLL4 is a potential therapeutic target.
Insights
High delta-like ligand 4 (DLL4) expression in gastric cancer patients is linked to poorer survival rates. This finding suggests DLL4 could be a potential therapeutic target for anti-angiogenesis drugs in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Delta-like ligand 4 (DLL4) and the Notch pathway are emerging targets for anti-angiogenesis cancer therapies.
- The specific role of DLL4 in gastric cancer (GC) prognosis remains largely undefined.
Purpose of the Study:
- To investigate the impact of DLL4 overexpression on recurrence and survival in gastric cancer (GC) patients.
- To determine if DLL4 expression levels correlate with clinicopathological parameters and patient outcomes.
Main Methods:
- Immunohistochemistry was used to assess DLL4 expression in 336 GC patient tissue samples.
- Patients were categorized into high and low DLL4 expression groups based on a 50% positive staining threshold.
- Statistical analyses correlated DLL4 expression with disease-free survival (DFS) and overall survival (OS).
Main Results:
- High DLL4 expression was found in 19.9% of GC patients.
- Patients with high DLL4 expression, particularly those in stages II-IV, exhibited significantly poorer DFS and OS after curative surgery.
- The negative impact of high DLL4 expression on survival was more pronounced in advanced stages (IIIb/IV).
Conclusions:
- Elevated DLL4 expression is a significant indicator of poor prognosis in gastric cancer patients.
- DLL4's association with adverse survival outcomes highlights its potential as a therapeutic target for novel anti-angiogenesis treatments in GC.
- Further research into DLL4-targeted therapies is warranted for gastric cancer management.
More Related Videos
Related Concept Videos
The Delta-to-Delta Circuit
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Correlations
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
The Y-to-Delta Circuit
The initial step in analyzing a wye-to-delta circuit is to assume a positive phase sequence. These phase voltages are then utilized to calculate the line voltages that occur directly across the delta-connected load impedances. Van, Vbn, and Vcn are the phase voltages in wye, and Vab, Vbc, and Vca are the line voltages for a delta circuit. The relation between...
The Delta-to-Y Circuit

